Prescient Therapeutics’ Post

Hear from Prof. Felix JF Herth as he discusses insights from his recent study on cautery cryobiopsy in Primary Mediastinal Large B-Cell Lymphoma at the recent WCBIP. He shares perspectives on diagnostic yield and procedure time, exploring this approach within mediastinal diagnostics. #Pulmonology #cryobiopsy

As healthcare marketers, understanding the complexities of specific conditions like peripheral T-cell lymphoma (PTCL) is crucial. Recent insights presented by Dr. Neha Mehta-Shah reveal a modest 5-year survival of 25-35% for PTCL patients. Emerging therapies and tailored treatment strategies show promise in improving outcomes. It's vital for us to leverage such knowledge in our strategies, ensuring patient-centric communication while navigating the evolving landscape of specialty oncology marketing.

Gates Institute member Manali Kamdar, MD first-authored their preliminary data using CD19x22 for non-Hodgkin Lymphoma at the American Society of Hematology (ASH) Conference. This groundbreaking innovation using two chimeric antigen receptors (CARs) in a single delivery vessel is a leading development in the field of CAR T-cell therapy. Additional authors from the Gates Institute include Executive Director Terry Fry, MD, Michael Verneris, MD, Navin Pinto, MD, Andrew Roth, Ph.D., and Cheri Adams, MSHS, RN, RAC. Congratulations to all of the exceptional authors from the University of Colorado Anschutz Medical Campus on this impactful publication! Read the abstract here: https://shorturl.at/2HV7v

In this recent open access publication, copanlisib, a phosphatidylinositol 3-kinase (PI3K) inhibitor approved for relapsed follicular lymphoma, exposure-efficacy relationships were considered from its large phase III trial, CHRONOS-3, whereas copanlisib safety was investigated by pooling data across its two large clinical trials to comprehensively assess its exposure-safety relationships. A unique model-based framework substantiated the overall positive benefit/risk assessment of the copanlisib 60 mg on days 1, 8, and 15 of a 28-day cycle dosing regimen. Aurexel provided scientific writing support on this important paper. #cancertherapy #hematologicalcancers #scientificwriting #adverseevents #bayerhealthcare #copanlisib #medicalwriting https://lnkd.in/dC2ZSzVi

Amidst the current buzz surrounding Burkitt Lymphoma, I would like to share some insightful perspectives. Let's explore the key facets of this topic together. #burkittlymphoma #lymphoma #cancerawareness #drswagatdash #shrc

September 15th is World #Lymphoma Awareness Day! 🩸📣 Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, provides an insight into the future of #CARTCell therapy for #Lymphoma, including #DLBCL, #MantleCellLymphoma, & #FollicularLymphoma 🔦 Although CAR-T is most well-established in #DLBCL, there is ongoing investigation to move #CART into earlier lines of therapy in all of these #hematologicalmalignancies, especially in high-risk patients. #Translational and #clinical research is playing a role in increasing the efficacy of CAR-T products while decreasing manufacturing time and associated #toxicities Prof. Sureda also highlights that the development of #allogeneic #CARTcells will likely overcome some of the challenges associated with #autologous CAR-T 💡 Learn more 👉 https://lnkd.in/ePBvx42g #LymSM #VJHemOnc #WLAD2024 #WorldLymphomaAwarenessDay #BloodCancerAwarenessMonth

🔬 Revolutionizing #CancerCare: The Role of CAR T-Cell Therapy in Non-Hodgkin's Lymphoma DelveInsight Business Research LLP’s latest report on the CAR T-Cell Therapy for #NonHodgkinsLymphoma Market dives deep into the evolving landscape of precision medicine. Explore key insights on market trends, emerging players, innovative therapies, and the future outlook for #CARTcell advancements in #oncology. The leading CAR T-Cell Therapy for Non-Hodgkin's lymphoma Companies such as Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Mustang Bio, CRISPR Therapeutics, 2seventy bio, Imugene Limited, and others. 🌟 Stay informed. Stay ahead. 📖 Read More Here @ https://lnkd.in/e74FjtZK #CARTCellTherapy #NonHodgkinsLymphoma #OncologyMarket #DelveInsight #CancerResearch #HealthcareInnovation

Molecular classification of DLBCL Solid table for lymphoma geeks such as myself https://lnkd.in/dmKmDrBE

Please join Stanford oncologist Ash Alizadeh's presentation at #ASH2024, where he will provide an in-depth overview of the #ALPHA3 trial conducted by Allogene Therapeutics. The ALPHA3 trial is exploring the use of novel “off-she-shelf” (or allogeneic) #CART for first-line consolidation therapy in large B-cell lymphoma (#LBCL). The trial utilizes an investigational ultra-sensitive minimal residual disease (#MRD) detection by Foresight CLARITY™ to identify MRD-positive patients for enrollment. We will examine how integrating cutting-edge diagnostics with next-generation, off-the-shelf CAR T therapies could transform current treatment approaches, expedite CAR T access—especially in community settings—and ultimately enhance cure rates for LBCL. This event is open to all ASH registrants. Add to calendar -> https://t.ly/1z5sa

Today we announced our first abstract on CRG-023 to be presented at the @American Society of Hematology Annual Meeting in San Diego. CRG-023 is a CD19-, CD20- and CD22-targeting tri-specific, tri-cistronic CAR T product candidate designed to provide more patients with a broad range of B-cell malignancies with durable responses, resulting in a potential best-in-class CAR T-cell therapy. Encouraging preclinical data showed sustained, durable anti-B cell lymphoma activity. CRG-023 represents the next step in our mission to develop best-in-class, potentially curative CAR T-cell therapies. Read more about the abstract and poster presentation details here: https://bit.ly/3UD0vlS #ASH24 #celltherapy